Introduction
The epidermal growth factor receptor (EGFR) belongs to the human epidermal growth factor receptor (HER) family of tyrosine kinase receptors (Bacus et al., 1994; DiFiore et al., 1978) . Elevated levels of HER1 have been identi®ed in human breast cancer (Biscardi et al., 1998) . Overexpression/ampli®cation of the EGFR (HER1) has been correlated with the development and progression of several types of human cancers (Ullrich and Schlessinger, 1990; Bacus et al., 1994) . Overexpression of HER1 transforms NIH3T3 cells in a ligand dependent manner and functions as an oncogene. HER2 (c-erbB2/p185 c-erbB2 ) shows extensive homology to receptors for epidermal growth factor (Ullrich et al., 1984) . HER2 ampli®cation/overexpression appears in a variety of human adenocarcinomas (Slamon et al., 1987 (Slamon et al., , 1989 Hynes, 1993) and HER2 overexpression in NIH3T3 ®broblasts also leads to malignant transformation (Baasner et al., 1996) .
EGFR speci®c intracellular signaling pathways and downstream growth regulatory genes have been described. Binding of EGF to its receptor results in activation of receptor tyrosine kinases, which recruit SH2 containing signaling molecules and lead to activation of ras, raf and MAP kinases (Pawson, 1994; Schlessinger and Ullrich, 1992) . MAP kinase translocates into the nucleus upon activation and phosphorylates a variety of transcription factors, e.g. c-jun (Karin and Hunter, 1995) . In recent years another signaling pathway has been discovered in which SH2 domain containing STAT (signal transducer and activator of transcription) proteins are directly activated by the EGFR kinase (Park et al., 1996; Quelle et al., 1995; Garcia et al., 1997) . As a consequence these proteins translocate into the nucleus and act as transcriptional activators (Shual et al., 1993) .
IRF-1 is a nuclear transcriptional activator. Its transcription is induced by various cytokines and hormones. Typical inducers of IRF-1 are interferons, TNFa, IL-1, IL-6, dsRNA and viruses. IRF-1 induces IFN stimulated genes, e.g. MHC class I (Hobart et al., 1996; Salkowski et al., 1996) , iNOS (Kamijo et al., 1994) and GBP (Briken et al., 1995) . IRF-1 is also necessary for proper expression of IL-15 (Ogasawara et al., 1998) , p21 (Tanaka et al., 1996) , and IFN-b (Fujita et al., 1993) . Studies with IRF-1 knock-out cells demonstrate that IRF-1 is involved in the differentiation and function of NK cells (Ohteki et al., 1998; Ogasawara et al., 1998) , in the generation of the TH 1 type of T helper cell and DNA damage (Tamura et al., 1997; Tanaka et al., 1996) . Moreover, IRF-1 shows tumor suppressor activity under certain conditions (Tanaka et al., 1994b (Tanaka et al., , 1996 and IRF-1 overexpression inhibits cell growth (Kirchho et al., 1993) . Embryonic ®broblasts de®cient in IRF-1 genes become transformed by a single oncogene (c-Ha-ras). These cells do not undergo apoptosis upon c-Ha-ras oncogene expression and serum starvation whereas wild type cells harboring IRF-1 genes undergo programmed cell death (Tanaka et al., 1994a) .
Although it is generally accepted that IRF-1 acts as a cell growth inhibitor, little is known about the growth of tumor cells expressing active IRF-1 and the mechanism of growth inhibition. In this study, we describe features of IRF-1 mediated growth inhibition of tumor cells. We use a fusion protein in which IRF-1 is fused to the hormone binding domain of the human estrogen receptor (hER), thus rendering IRF-1 function dependent on b-estradiol activation. bestradiol treatment leads to a strong proliferation inhibition and cell death of various transformed cell lines expressing the fusion protein. NIH3T3 cell lines overexpressing HER1 protein and transformed by the administration of EGF are included in this study. In these cells, activation of IRF-1 or HER1 alone does not result in apoptosis. In contrast, when both the oncogene and the tumor suppressor are activated the cells are killed by apoptosis. Furthermore, activation of both proteins results in the synergistic activation of various promoters. Both phenotypes can be blocked by overexpression of a dominant negative mutant of STAT5a, but not by inhibition of the EGF induced ras pathway.
Results

IRF-1 inhibits cell growth of transformed cell lines
To determine the activity of IRF-1 as a growth inhibitor of transformed and tumor cell lines, we expressed IRF-1 as an activatable fusion protein. The fusion protein consists of the complete IRF-1 protein and the hormone binding domain of the human estrogen receptor (IRF-1-hER). Functional activation of IRF-1 in this fusion protein is induced by treatment with b-estradiol and results in an inhibition of cell growth (Kirchho et al., 1993 (Kirchho et al., , 1995 . IRF-1-hER was transfected into the following cell lines: (a) NIH3T3 cells expressing the Adenovirus proteins E1a/b; (b) The sarcoma cell line BC1 in which the transforming proteins are unknown; (c) The MMV (Mouse Molony Virus) transformed mouse ®broblastoid cell line C243 (Oie et al., 1997) ; (d) NIH3T3 cells expressing the HER1 oncogene. Oncogenicity in this cell line is induced when HER1 is activated by the addition of EGF. Untransformed NIH3T3 cells expressing IRF-1-hER were used as a control (Kirchho et al., 1995) . Cell growth was determined 4 days after IRF-1 activation. As shown in Figure 1a all cell lines were sensitive to IRF-1 activity with respect to growth inhibition, but the extent of proliferation inhibition varied signi®cantly. The E1a/b transformed cell line showed a reduction in proliferation of only approximately 20% in comparison to the untreated cells, whereas the C243 cell line showed a growth inhibition of 90%. The strongest inhibition (98%) was seen in the NIH3T3 cell line expressing the activated HER1 oncogene. The nontransformed NIH3T3 cell line expressing IRF-1-hER alone showed 60% growth inhibition. The corresponding cells which did not express IRF-1-hER did not respond to b-estradiol with growth inhibition (Figure 1a , NIH3T3 left columns). Thus, IRF-1 inhibits the growth of all the cell lines tested in this experiment. However, the extent of proliferation inhibition varied signi®cantly among the dierent cell lines.
To determine whether IRF-1 reverses the transformed phenotype of these tumor cell lines, we tested their ability to grow in soft agar in the presence of inactive or activated IRF-1 (Figure 1b) . Whereas NIH3T3 cells did not grow in soft agar, all tumor cell lines gave rise to soft agar clones. This ability was totally abolished by the activation of IRF-1. The growth in soft agar of the transformed cell lines not expressing IRF-1-hER was not in¯uenced by b- Figure 1 IRF-1 inhibits cell growth of transformed cell lines. Cell growth inhibition and the formation of soft agar colonies were measured in NIH3T3, C243 cells and BC1 cells. The cell lines were either stably transfected with an expression construct for IRF-1-hER (boxed) or an empty vector in an untransformed NIH3T3 background or in a transformed (boxed) background. HER1 in NIH3T3 HER1 cells is constitutively expressed and was activated by 20 ng/ml EGF. (a) The percentage of growth inhibition of the indicated cell lines after 4 days of activation with b-estradiol (+E2; 1 mM) is shown. Cell growth inhibition of untreated cells was used as a control (C). (b) The number of colonies of the indicated cell lines without (C) or with b-estradiol (+E2; 1 mM) was determined after 9 days of growth in soft agar Figure 1a and b). The data suggest that IRF-1 mediated proliferation inhibition in soft agar depends on the degree of oncogenic transformation.
HER1 and HER2 enhance the growth inhibitory eect of IRF-1
We deduced from the experiments described above that the ability of IRF-1 to inhibit cell growth is increased in transformed cells. We focused on the NIH3T3 cell line which expresses HER1 and IRF-1-hER. The transformed state of this cell line is induced by the addition of EGF. This allowed us to directly compare the eect of IRF-1 in the nontransformed state with the transformed state. Compared with the other cell lines (Figure 1b ) it appears that after activation of HER1 this cell line shows the strongest oncogenicity. We also used an NIH3T3 cell line in which the HER2 cDNA is under the control of the tetracycline regulatable promoter (Baasner et al., 1996) . This cell line becomes transformed by transcriptional activation of HER2 after tetracycline depletion. IRF-1-hER was stably established in this cell line. RF-1 was shown to be activated by b-estradiol in both cell lines in the normal and in the transformed state (Figure 2a and b) . The amount of secreted interferon which is typically induced by IRF-1 Figure 2 HER oncogenes enhance IRF-1 mediated cell growth inhibition. Cell growth was measured in NIH3T3 cells which constitutively express IRF-1-hER together with HER1 (a, c) or constitutively express IRF-1-hER together with the HER2 oncogene under the control of a tetracycline modulatable promoter (tTA) (b). For determination of cell growth, the metabolic activity of the cultures was measured after 3 days of the respective treatment. The metabolic activity of untreated cells was set to 100%. Secreted interferon (right panels a and b) was measured 24 h after onset of IRF-1 activity (+E2) in the presence (+EGF) or absence (C) of the activated HER1 oncogene. (a) IRF-1 and HER1 were activated alone or together. Cells with inactive (no b-estradiol) or activated IRF-1-hER (1000 nM bestradiol) were stimulated with EGF (20 ng/ml) or left without EGF (C). (b) IRF-1 and HER1 were activated alone or together. Expression of the constitutively active oncogene HER2 is regulated by omission (7tet, induced) or addition (+tet, uninduced) of tetracycline (1000 ng/ml). IRF-1-hER was activated by b-estradiol. (c) Growth of the cells treated with 6 mM bestradiol and the indicated EGF concentrations Cooperation of HER and IRF-1 S Kirchhoff and H Hauser (Kirchho et al., 1995) can be taken as a measure for IRF-1 activity (data not shown). No dierence in the amount of interferon detected in the supernatants of both cell lines was determined in the absence or presence of the active HER oncogene, indicating that IRF-1-hER is equally expressed in both states. However, the cells expressing HER1 secreted more interferon when compared to the HER2 expressing cells (6000 versus 2000 U/ml in Figure 2a and b) .
The growth of both cell lines measured by their metabolic activity was plotted after 3 days of HER oncogene activation. The cell line expressing inactive HER1 was responsive to IRF-1 and showed about 50% of the cell growth in the presence of 1 mM bestradiol when compared to the untreated control (Figure 2a ). Simultaneous activation of HER1 and IRF-1 resulted in a drastic reduction of the cell counts (10% of the untreated control culture; Figure 2a ). Cells treated with EGF alone showed a slightly (around 5%) enhanced proliferative capacity in comparison with the control cells. Figure 2b demonstrates that the enhanced inhibition of proliferation was also detected in HER2 transformed cells. Inhibition of proliferation mediated by IRF-1 was strongly enhanced in the presence of active HER2 (7tet) when compared to the inhibition mediated by IRF-1 alone.
To further support the hypothesis that IRF-1 mediated growth inhibition is increased in transformed cells, we determined the growth of HER1 expressing cells treated with dierent concentrations of EGF after 3 days of IRF-1 activation. Since the extent of growth inhibition depends on the concentration of b-estradiol (Kirchho et al., 1995) a moderate concentration of 6 nM b-estradiol was used. This led to a growth inhibition of over 50% after 3 days of treatment with b-estradiol in the absence of activated HER1 (no EGF; Figure 2c ) and therefore enabled us to detect dierences in proliferation even at high EGF concentrations. Figure 2c shows that increasing concentrations of EGF caused a decrease in proliferation (up to 92% of the control in the presence of 20 ng/ml EGF). NIH3T3 cells expressing IRF-1-hER but not HER1 were treated in the same way. Here EGF did not cause a further reduction in proliferation (data not shown). This result indicates that expression of HER1 is a prerequisite for enhanced inhibition of proliferation. Furthermore, the data show that the extent of cell growth inhibition depends on the amount of active HER1.
In the experiments described so far, the activation of oncogenes and IRF-1 occurred simultaneously. To examine whether IRF-1 can also inhibit the growth of cells already expressing active oncogenes, we repeated the experiments with cells expressing activated HER oncogenes for 24 or 48 h. In this type of experiment, enhanced inhibition of cell growth was also detected (data not shown). This indicates that previously transformed cells are also strongly inhibited as a consequence of IRF-1 activation.
Simultaneous activation of HER1 and IRF-1 leads to cell death
The growth kinetics of cells in which IRF-1 and HER1 are activated simultaneously were determined. These kinetics were compared with cells in which IRF-1 was activated alone. Growth of the untreated cultures was also followed and served as a control; these values were set to 100%. Detectable growth inhibition was seen after 1 day of treatment (Figure 3a ). Between day 1 and day 2 of treatment, growth was strongly reduced; after 3 days of treatment, cell growth was close to zero. To investigate whether cells in which IRF-1 and HER1 were activated stopped growing or died the number of viable cells was counted by trypan blue exclusion. As illustrated in Figure 3b , 3 days after induction no viable cells in the EGF and bestradiol treated cell population were detectable. In contrast, cells expressing activated IRF-1 alone contained approximately the same amount of viable cells as before treatment. These experiments clearly demonstrate that the simultaneous activity of IRF-1 and HER1 induces cell death.
Externalization of membrane phosphatidyl serine (PS), one of the earliest signs of apoptosis, is detectable by Annexin V staining (Fadok et al., 1992; Martin et al., 1991; Verhoven et al., 1995) . The presence of Annexin V + /PI 7 cells is indicative of preapoptotic cells, while such staining is not seen in the case of death by necrosis (Kroemer, 1995) . To test whether apoptosis is involved in IRF-1 mediated cell killing in HER1 expressing cells, NIH3T3 cells expressing HER1 and IRF-1-hER were incubated with EGF and/or bestradiol for 2 days and stained with FITC-conjugated Annexin V. Propidium iodide (PI) was used as a marker for cellular destruction. We noted a population of cells treated with EGF plus b-estradiol which showed a marked increase (23%) /PI + cells also indicates that in a minor cell population cell death was caused by as yet unidenti®ed mechanism in a minor population.
IRF-1 mediated cell death was also associated with a nuclear DNA degradation into oligonucleotide fragments, one of the ®nal stages of apoptotic cell death. Twenty-®ve per cent of the cells with active HER1 and IRF-1 showed subdiploid DNA (fragmented DNA) (data not shown) (Nicoletti et al., 1991) . Cells in which either IRF-1 or HER1 were activated alone did not show DNA fragmentation. These results demonstrate that the cell line expressing activated IRF-1 together with activated HER1 underwent apoptosis accompanied by DNA degradation.
Synergistic activation of IRF-1 inducible promoters by IRF-1 and HER1
Since transcriptional activation by IRF-1 is a prerequisite for its growth inhibitory activity (Kirchho et al., 1993) , one explanation for the synergistic activity of IRF-1 and HER1 is that the EGFR signaling pathway enhances the transcriptional potential of IRF-1. Therefore, a number of promoters containing IRF-1 speci®c binding sites were tested for activation by IRF-1 and/or HER1. A construct containing a GAS (g-interferon activated sequence) element and the ISRE (interferon stimulated response Cooperation of HER and IRF-1 S Kirchhoff and H Hauser element) of the human GBP promoter (Lew et al., 1991 ; Figure 4a ) was made. In addition, another promoter construct containing the consensus sequence of an ISRE (interferon stimulated regulatory element, Figure 4b ) alone was used. Upon transient transfection into NIH3T3 cells expressing HER1 and IRF-1-hER both constructs were induced by IRF-1 activation (Figure 4a and b) . Activation of HER1 alone led to a minor induction of both promoters. However, IRF-1 mediated induction of both promoters was strongly enhanced by activation of HER1. The GAS-containing promoter construct was induced 29-fold by the combined action of HER1 and IRF-1, but only eightfold by IRF-1 alone and threefold by HER1 alone. The ISRE-containing promoter construct was induced 60-fold by both activities, but only 30-fold by IRF-1 and twofold by HER1 alone. Control transfections using NIH3T3 cells expressing IRF-1-hER alone did not results in enhanced transcriptional activation in the presence of EGF and b-estradiol. This result excludes a synergistic activity of IRF-1 with the endogenous EGFR in the untransformed cells (data not shown). To rule out the possibility that the enhanced transcriptional potential is a result of the estrogen receptor part of IRF-1-hER, an expression plasmid encoding w.t. IRF-1 was used instead of IRF-1-hER for monitoring the GASand ISRE-containing reporters. Activation of HER1 in IRF-1 expressing cells led to transcriptional enhancement of both promoter constructs to the same extent as that induced by IRF-1-hER (data not shown). To determine whether HER1 signaling leads to a posttranslational modi®cation of IRF-1, e.g. phosphorylation and thereby enhances its transcriptional activity, the eect of HER1 on the transcriptional potential of IRF-1 was investigated. A GAL4*IRF-1 fusion protein expression construct was transfected into HER1 cells (Figure 5a ) together with a GAL4 sensitive promoter. GAL*IRF-1 induces the GAL sensitive promoter construct ®vefold, but induction is not modulated by EGF. However, as expected, EGF increases the transcriptional potential of a GAL4*STAT1 fusion protein (Figure 5a ). Another reporter construct containing several IRF-1 responsive elements (IRE) from the ICE promoter was tested. IRF-1 mediated induction of this construct was not enhanced by the addition of EGF, indicating that the DNA-binding capacity as well as the transcriptional potential of IRF-1 were not altered (Figure 5b) . The basal activity of this construct was not induced by EGF alone. These observations are in line with the fact that we did not detect any dierences in the amount of secreted interferon as shown in Figure 2 . The arti®cial promoter constructs behave in the same manner. This observation rules out the possibility that the HER enhanced induction of the GAS-and ISRE-containing reporter constructs is due to EGF-mediated enhancement of the DNA-binding or transcriptional activation capacity of IRF-1.
IRF-1 does not modulate the ras/STAT pathway
Another possible explanation for the synergistic transactivation of the reporter constructs mediated by HER1 and IRF-1 is that IRF-1 may in¯uence HER1 signaling. To examine this possibility the induction of two reporter constructs which can only be induced by HER1 but not by IRF-1 was determined before and after activation of IRF-1. We focused on the two well known EGFR signaling pathways, namely the ras/ MAPK and the STAT pathway. The ®rst reporter construct which was used for these experiments contains the promoter of the cis gene which is sensitive to STAT activity (SRE; Figure 6a ). The second construct contains a part of the collagenase promoter (773/ +63) (Angel et al., 1987; Schneikert et al., 1996) which is sensitive to the ras pathway mediated by API (ras as responsive element in Figure 6b ). As depicted in Figure  6a and 7b both constructs were induced by HER1 signaling up to threefold but the induction was not altered after activation of IRF-1. From these results we conclude that IRF-1 and HER1 signaling pathways act in synergy but do not in¯uence each other directly.
The ras pathway is not involved in the transcriptional synergistic activity of IRF-1 and HER1
To determine whether one of the above mentioned signal transduction pathways activated by HER1 is responsible for the synergistic activity with IRF-1, we tested the transcriptional synergy in the presence of dominant negative mutants of ras or STAT. An expression construct coding for the dominant negative ras, rasAsn17 (de Vries-Smits et al., 1992), together with a ras-sensitive promoter (7517/+63 from the collagenase promoter; Figure 7a) (Angel et al., 1987; Schneikert et al., 1996) construct or with the GAScontaining construct (Figure 7b ) was transiently transfected into the NIH3T3 cell line expressing Cooperation of HER and IRF-1 S Kirchhoff and H Hauser HER1 and IRF-1-hER. EGF treatment led to a 25-fold induction of the ras sensitive promoter. Induction was diminished in the presence of the rasAsn17 mutant protein demonstrating the functionality of the mutant in this cell line. In contrast, rasAsn17 neither in¯uenced HER1 mediated expression of the GAScontaining promoter construct nor inhibited the synergistic activation mediated by IRF-1 and HER1 (Figure 7b) . Unexpectedly, endogenous ras appeared to reduce the transcriptional of IRF-1 since IRF-1 mediated induction was slightly enhanced in the presence of rasAsn17. These experiments indicate that the ras pathway slightly reduces the transcriptional potential of IRF-1 but does not play a role in the synergistic activity of IRF-1 and activated HER1.
STAT5 is involved in the synergistic activity of IRF-1 and HER1
We also investigated a possible in¯uence by the STAT signaling pathway. We focused on STAT5 for the following reasons: EGFR activation leads to the activation of STAT1, STAT3 and STAT5 (Shual et al., 1993; Zhong et al., 1994; Ru-Jamison et al., 1995) . STAT1 and STAT3 are activated by IFN-b. If these STAT proteins had been responsible for the synergistic activity of IRF-1 and HER1, we also should have seen this eect upon activation of IFN-b. However, this was not the case (data not shown). A dominant negative version of STAT5a, STAT5aD750, together with a STAT sensitive reporter (Figure 8a ) or the GAScontaining reporter (Figure 8b ) was transiently transfected into NIH3T3 cells expressing IRF-1-hER and HER1. Figure 8a indicates that, as expected, the STAT5 dominant negative protein STAT5aD750 (Moriggl et al., 1996) inhibited the induction of the STAT responsive promoter construct after addition of EGF. In addition, the presence of STAT5aD750 abolished the synergistic activity of HER1 signaling and IRF-1 when the GAS-containing promoter construct (Figure 8b ) or the ISRE-containing construct were used (Figure 8c ). We con®rmed that the dominant negative STAT5a protein does not cause a general inhibition of HER1 expression/function by checking HER1 mediated induction of the ras responsive promoter construct during expression of the STAT mutant. As shown in Figure 8d , this induction was not modulated, indicating that STAT5aD750 acts speci®cally in the STAT pathway.
STAT5 protein is responsible for IRF-1 and HER1 mediated apoptosis
The synergistic eect of HER1 and IRF-1 activation on gene induction shows a direct correlation to proliferation inhibition. Activated HER1 together with IRF-1 results in enhanced cell growth inhibition as well as in an increased transcriptional activation. Since the STAT5 mutant inhibited this synergism on the transcriptional level we asked whether the dominant negative STAT5 protein could also abrogate enhanced growth inhibition and cell death (Figure 3c ). Stable transfectants expressing either STAT5aD750, the dominant negative version of ras, or an empty vector were isolated from IRF-1-hER plus HER1 positive cells. IRF-1 was activated by b-estradiol (1 mM) and HER1 by EGF (20 ng/ml). Forty-eight hours after hormone addition, cell growth was determined. As shown in Figure 9 , IRF-1 reduced the cell counts to 50% in comparison with the control transfectants. In the presence of HER1, the cell counts were reduced to 25%. In the presence of STAT5aD750, enhancement of cell growth inhibition was totally abolished. In contrast, the expression of rasAsn17 increased IRF-1 mediated cell growth inhibition, from 50 ± 60% (only 40% cell growth in comparison to the control) suggesting that the ras pathway counteracts the growth inhibitor function of IRF-1 marginally. The eect of the rat dominant negative mutant is more prominent in the cell culture expressing activated IRF-1 and HER1. Here cell growth was reduced from 30 ± 10%. Interestingly, this also resembles the eect on transcription. In the presence of the dominant negative protein the induction of the GAS-containing promoter construct was also further increased (Figure 7b ). Taken together, these results demonstrate that the STAT5 protein is an important target of HER1 signaling in the synergistic action with IRF-1 that determines cell growth and transcription. Moreover, endogenous ras appears to counteract IRF-1 mediated inhibition of proliferation.
Discussion
In this report we demonstrate that IRF-1 inhibits growth of dierent cell lines. These cell lines include NIH3T3 transformed by E1a/b, MMV infected mouse ®broblasts and a human sarcoma cell line. Moreover, transformation mediated by the EGFR derivates HER1 and HER2, a common feature of human tumor cells (Garcia et al., 1997) , is also inhibited. Previously, it was shown that IRF-1 can suppress cellular transformation induced by dierent oncogenes, such as myc, fosB (Tanaka et al., 1994b) and IRF-2 (Harada et al., 1993; Futaki et al., 1996) . Thus, our results, together with earlier reports, support the de®nition of IRF-1 as a tumor suppressor protein.
The mechanism of transformation-inhibition by IRF-1 is not well understood. IRF-1 exerts its antiproliferative eect by DNA binding and transactivation (Kirfchho et al., 1993) . Since HER1 activation leads to a stimulation of transcription of IRF-1 dependent promoters the modulation of gene expression appears to be a prerequisite for the transformation-inhibiting activity of IRF-1. IRF-1 is known to induce a number of genes which exert growth inhibitory eects. Among them are Lysyl oxidase (Tan et al., 1996) , PKR (Tanaka and Samuel, 1994; Kirchho et al., 1995) , 2' ± 5' OASE (Benech et al., 1987) , Indoleamine 2,3-dioxigenase (Takikawa et al., 1988) , and Angiotensin type II receptor (Horiuchi et al., 1997) . Furthermore, the promoter regions of certain caspase genes like ICE containing ISRE-like sequences (Chin et al., 1997) . These genes might be targets for IRF-1 (Tamura et al., 1997) . In established cell lines of ®broblast and epithelial origin, IRF-1 leads to cell growth arrest with no typical signs of apoptosis (compare Figure 3) . A fusion protein of IRF-1 and the strong transactivation domain of p65 (RelA) was described to result in DNA condensation (Nguyen et al., 1997) . However, it was not speci®ed if this is the result of apoptotic or necrotic events. In our study the combined activity of HER1 and IRF-1 in NIH3T3 cells leads to signi®cant cell death by apoptosis. This is in accordance with results obtained earlier with embryonic ®broblasts from IRF-1 7/7 in which expression of cHa-ras oncogene in wild type cells but not in IRF-1 7/7 cells forces the cells to undergo apoptosis under growth restricted conditions (Tanaka et al., 1994a) . The combined activity of IRF-1 and HER1 is an example of oncogene dependent tumor suppressor mediated apoptosis. This is similar to the activity of the tumor suppressor p53 required for ras induced apoptosis (Lowe and Ruley 1993; Attardi et al., 1996) .
Another report by Sala et al. (1996) shows that overexpression of the protooncogene c-myb stimulates apoptosis when coexpressed with p53. In that case apoptosis is accompanied by increased transactivation of the proapoptotic gene BAX, which might be the mediator for the apoptotic event. Although BAX expression is not modulated during the combined activation of HER1 and IRF-1 (data not shown) the experiments demonstrate a further similarity between IRF-1 and p53. It has been reported earlier that both tumor suppressor proteins cooperate in response to DNA damage (Tamura et al., 1995; Tanaka et al., 1996) .
We have uncovered a component of the synergistic activation of apoptosis by HER1 and IRF-1 activation. Using the dominant negative mutant of STAT5, STAT5aD750 (Moriggl et al., 1996) , we could show the STAT5 signaling is essential for this transcriptional synergy. Thus, STAT5 might synergize directly with IRF-1 on these promoters. The principle of synergistic action of transcription factors with IRF-1 is quite common; IRF-1 has been shown to cooperatively interact with TFIIB (Wang et al., 1996) ; NF-kB (Drew et al., 1995) , and STAT1 (Chon et al., 1996) . It is also described that IRF-1 together with p53 induces the cell cycle inhibitor p21 (Tanaka et al., 1996) . However, so far we were not able to detect a direct interaction of IRF-1 with one of the STAT proteins, neither by gel retardation nor by a two hybrid system in mammalian cells (data not shown).
EGF-receptor enforced apoptosis of IRF-1 expressing cells is paralleled by the strongly enhanced transcriptional activation of several promoter constructs containing IRF-1 and EGF responsive sites (Figure 4 ). Since expression of the dominant negative STAT5 protein abolishes the synergistic activity on transcription, as well as the jointly induced apoptosis, it is tempting to speculate that the enforcement of certain IRF-1 responsive genes might be responsible for the induction of apoptosis. Proapoptotic genes might be the target for the synergistic activity between IRF-1 and STAT5. Although this is possible we cannot exclude that STAT5 also induces other genes independent of IRF-1 which lead to downstream interactions with IRF-1 induced gene products. Recently, Bovolenta et al. (1998) identi®ed a naturally occurring C-truncated STAT5 isoform which coincides Figure 9 Reversal of apoptosis by STAT5 inhibition. Cell growth was measured in three NIH3T3 cell lines constitutively expressing HER1 and IRF-1-hER together with a control vector or an expression plasmid encoding STAT5aD750 (muSTAT5, black bars) or H-rasAsn17, stippled bars). Cell growth of untreated cultures was set to 100%. Cells were treated for 48 h with 20 ng/ml EGF and/or 1 mM b-estradiol as indicated with apoptosis survival and acts in a dominant negative manner (Bovolenta et al., 1998) .
EGFR signaling includes the activation of STAT1, STAT3 and STAT5 (Shual et al., 1993; Zhong et al., 1994; Ru-Jamison et al., 1995) . STAT3 was described to be constitutively active in various transformed cells and shows a high frequency of activation in breast cancer carcinoma cells (Danial et al., 1995; Garcia et al., 1997) and seems to be responsible for this transformed phenotype. STAT3 is also found to be constitutively active in breast cancer cells which show elevated expression of EGFR and c-src (Garcia et al., 1997) . STAT3 activation is required for transformation by v-src (Bromberg et al., 1998) . STAT5 is constitutively active in BCR-Abl transformed cells (Shuai et al., 1996; Chai et al., 1996) . It is therefore possible that the STAT5 protein contributes to the transformed phenotype in HER1 and HER2 cells.
EGFR (Chin et al., 1997) as well as c-myc (Evan et al., 1992) have dual activity: Depending on the environmental conditions, they induce proliferation or apoptosis. In cells growing at a normal rate, these events are balanced. Overexpression of EGFR in some cells results in proliferation due to a higher amount of survival factors suppressing the apoptotic pathway. Similar data have been described for the protooncogene c-myc (Mayo et al., 1997) . Considering the dual activity of the HER oncogenes, IRF-1 might in¯uence the balance of proliferation versus apoptosis. This could be achieved in dierent ways ( The results presented here indicate that IRF-1 induces apoptosis speci®cally in transformed cells. In nontransformed cells IRF-1 only reduces their proliferative capacity. IRF-1 mediated apoptosis in oncogenic cells could provide a mechanism for the elimination of cells that escaped primary growth control. In addition, IRF-1 has several other antitumor activities, relevant in vivo. These are due to the immunomodulatory eects of IRF-1, such as the stimulation of T-helper cells and NK cells (Duncan et al., 1996; Loho et al., 1997) , transcriptional enhancement of MHC genes (Kirchho et al., 1993; Drew et al., 1995; Massa and Wu, 1995; Hobart et al., 1996) and of genes involved in antigen presentation (White et al., 1996; Chatterjee-Kishore et al., 1998) . Thus, most events or drugs which enhance the expression or activity of IRF-1 might be useful in cancer therapy by inducing speci®c killing of transformed cells. Indeed, experiments on mice have been described which show that expression of IRF-1 in aggressive nonimmunogenic sarcoma cells suppress the malignant phenotype (Yim et al., 1997) . Taken together, our data provide further molecular insight into the role of IRF-1 in antitumor responses.
Materials and methods
Establishment and induction of recombinant mammalian cells
NIH3T3 cells, the human sarcoma cell line BC1, C243 cells (Oie et al., 1977) were stably cotransfected with an expression construct encoding IRF-1-hER (Kirchho et al., 1993) , and a hygromycin resistance conferring plasmid (Blochlinger and Diggelmann, 1984) . Cell lines expressing HER1 or HER2 together with IRF-1-hER were generated. NIH3T3 cell lines consitutively expressing HER1 or HER2 expressed under the control of the tetracycline modulatable promoter (tTA), were supertransfected with the expression vectors encoding IRF-1-hER together with the neomycin resistance expression construct (ColbeÁ re-Garapin, 1981). The IRF-1-hER coding sequence was constitutively expressed by the MT7 promoter (Kirchho et al., 1995) . Vectors encoding constitutively expressed dominant negative versions of STAT5aD750 or rasAsn17 together with a puromycin resistance plasmid (Vara et al., 1986) were supertransfected in a cell line in which HER1 and IRF-1-hER are expressed constitutively. From pools of resistant transfectants a series of cell clones were picked, expanded and tested. Results from individual cell clones were representative for the respective pools these clones were taken for the experiments shown here. The cells were grown in DME plus 10% of estrogen free fetal calf serum, antibiotics, glutamine and the respective selective drugs and tetracyclien (1 mg/ml). Tetracycline-containing media were renewed every 48 h. To activate IRF-1 in the IRF-1-hER fusion protein the medium was adjusted with bestradiol to the indicated concentration. For activation of HER1 the medium was adjusted to 20 ng/ml EGF (Sigma). For expression of tTA regulated HER2, the cells were washed several times and cultured without tetracycline (Kirchho et al., 1995; Baasner et al., 1996) .
DNA was transfected using calcium phosphate coprecipitation (Graham and van der Eb, 1973) . For the generation of stable transfectants 2610 5 cells/25 cm 2 ask were seeded. Five mg eector DNA together with 0.5 mg of the drug resistance plasmid was transfected. Selection pressure was initiated 48 h after transfection.
Measurement of cell growth, apoptosis and transformation
For determination of cell growth 4000 cells/well were seeded into microtiter plates and serial dilutions (1 : 1) were performed allowing several independent measurement points. Cells were treated with the indicated concentrations of b-estradiol and EGF. Cell growth was determined by using the WST kit from Boehringer/Mannheim following the manufacturer's instructions. Mean values of triplicates resulting in less than 10% deviation were plotted. Annexin V staining was performed according to the manufacturer's instructions (Clontech). DNA degradation was assessed by determination of DNA fragmentation after lysing the cells in a hypotonic buer (0.1% sodium citrate, 0.1% Triton X-100) containing 50 mg/ ml propidium iodide as described by Nicoletti et al. (1991) and analysed by¯ow cytometry using a FACScan analyser with CELLQUEST software (Becton-Dickinson, Heidelberg, Germany). In all cases 10 000 cells were analysed. For crystal violet staining 10 4 cells were seeded on 9-cm 2 wells. Cell treatment is indicated accordingly. After 3 days the plates were washed with PBS and stained. For determination of soft agar growth 1500 cells were seeded in 50 ml 0.3% overlay agar in microtiter plates coated with 50 ml 0.5% underlay agar. The induction medium was added to the top (50 ml).
Plasmid constructions
Constructions were carried out by standard procedures (Sambrook et al., 1989) . The constitutive expression vector for IRF-1-hER was described elsewhere (Kirchho et al., 1993) . GAL*IRF-1: a PCR-product coding for IRF-1 was integrated into the EcoRI site of pSGMT7 (Kirchho et al., 1998) . GAL*STAT1: The coding region for STAT1 was integrated into the EcoRI site of pSGMT7. The GAScontaining reporter plasmid was derived by the integration of an oligonucleotide containing four repeats of the GAS/ISRE element (5'gatccgaagtactttcagtttcatattactctaaatcca3') of the human GBP promoter into the BglII site of pGL2CVX (Promega); the other ISRE-containing reporter plasmid was created by integration of an oligonucleotide containing two repeats of the consensus ISRE element into pGL2CVX (5'actaaaagtcaaaggtaaagggctcttccctag3'). The IRF-1-responsive reporter construct (IRE) was described earlier (Kirchho et al., 1996) .
Analysis of gene products
Interferon concentration in the cell supernatants was determined by an antiviral assay employing mouse L929 cells (Dinter and Hauser, 1987) CAT analyses were performed using the CAT-ELISA (Boehringer/Mannheim) as described by the manufacturer's instructions. Extracts were prepared from transfected cells by the freezing and thawing method. Luciferase activity was measured as described by de Wet et al. (1987) . SEAP activity was measured in the supernatants as described in Kirchho et al. (1996) . The indicated results are based on more than three independent transfection experiments and normalized to protein concentration in the extracts. Relative induction numbers are mean values of three independently determined reporter activities. From a series of at least ®ve independent transient transfection experiments one representative is shown. 
